Senate Committee Hearing Examines the High Cost of Pharmaceutical Innovation
This is part 2 of Drug Topics’ coverage of the September 24th Senate Committee on Health, Education, Labor and Pension hearing on semaglutide pricing. Click here to read part 1 of our coverage. The main headline coming out of Novo Nordisk president and CEO …